Page 4 - Radek Spisek News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Radek spisek. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Radek Spisek Today - Breaking & Trending Today

Investegate |SOTIO Biotech Announcements | SOTIO Biotech: Data from SOTIO's Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors

Investegate announcements from SOTIO Biotech, Data from SOTIO’s Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors ....

United States , Comunidad Autonoma De Cataluna , Elena Garralda , Michael Tattory , Radek Spisek , Richard Kapsa , Lifesci Communications , American Society Of Clinical Oncology , Vall Dhebron Institute Of Oncology , Clinical Benefit , Valld Hebron Institute , Clinical Oncology , Annual Meeting , Investegate Announcements , Investegate Company Announcements , Sotio Biotech , Lobenewswire And Globenewswire ,

SOTIO Biotech: Data from SOTIO's Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid Tumors

Data demonstrate that SOT101 monotherapy and SOT101 in combination with pembrolizumab have a favorable safety profileEncouraging efficacy signals were observed for both SOT101 monotherapy and SOT101 in ....

United States , Comunidad Autonoma De Cataluna , Kostenloser Wertpapierhandel , Elena Garralda , Michael Tattory , Radek Spisek , Richard Kapsa , Lifesci Communications , American Society Of Clinical Oncology , Vall Dhebron Institute Of Oncology , Valld Hebron Institute , Clinical Oncology , Annual Meeting ,

SOTIO Biotech: SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer

CLAUDIO-01 is the first-in-human trial of SOT102, a CLDN18.2 (Claudin 18.2) targeting antibody-drug conjugate (ADC)The trial will enroll up to 109 patients with gastric and pancreatic cancer PRAGUE ....

Czech Republic , United States , Kostenloser Wertpapierhandel , Radka Obermannova , Josep Tabernero , Michael Tattory , Radek Spisek , Richard Kapsa , Lifesci Communications , Hebron University Hospital , Masaryk Memorial Cancer Institute , Medical Oncology ,

SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pa

CLAUDIO-01 is the first-in-human trial of SOT102, a 2 (Claudin 18.2) targeting antibody-drug conjugate (ADC) The trial will enroll up to 109 patients with gastric and pancreatic cancerPRAGUE, Czech Republic, April 26, 2022 / B3C newswire / SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group. ....

Czech Republic , United States , Radka Obermannova , Josep Tabernero , Michael Tattory , Radek Spisek , Richard Kapsa , Lifesci Communications , Hebron University Hospital , Masaryk Memorial Cancer Institute , Drug Development , Medical Oncology , Clinical Trials , Pancreatic Neoplasms , Esophagogastric Junction , Stomach Neoplasms ,

SOTIO Initiates CLAUDIO-01 Trial with Antibody-Drug Conjugate SOT102 in Patients with Gastric and Pancreatic Cancer

SOTIO Biotech, a clinical stage immuno-oncology company owned by PPF Group, announced today that it has dosed the first patient in its Phase 1/2 CLAUDIO-01 trial of SOT102 in patients with gastric and pancreatic cancer. SOT102 is the lead program of SOTIO’s growing ADC pipeline built on multiple platforms. “Antibody .. ....

Czech Republic , United States , Radka Obermannova , Josep Tabernero , Radek Spisek , Hebron University Hospital , Masaryk Memorial Cancer Institute , Medical Oncology ,